Podcast 62: A conversation with Jane Kim about cost-effectiveness of vaccinating women with HPV vaccine after age 30.

The FDA seems set to announce a decision about vaccinating women past age 25 for HPV. A paper in the Annals of Internal Medicine this week indicates that such a strategy wouldn’t be cost-effective.

Don’t be put off by “cost-effectiveness” or by the fact that we actually discuss “QALY”s. It’s all good. We’ve got Harvard School of Public Health’s Jane Kim to guide your interviewer through the QALY thicket, and she’s a great guide.

Contact us at 1-617-440-4374 or write to jelia@nejm.org.

This week’s links:

NEWS:

• Aldosterone Antagonists Underused in Heart Failure

• ACP Issues Guidelines on Hormonal Testing and Pharmacologic Management of Erectile Dysfunction

• Ketorolac for Injection Recalled

• Intensified BP Control Benefits Kids with Chronic Kidney Disease

INTERVIEW:

• Adding HPV Vaccination to U.S. Cervical Screening Isn’t Cost-Effective After Age 30

The post Podcast 62: A conversation with Jane Kim about cost-effectiveness of vaccinating women with HPV vaccine after age 30. first appeared on Clinical Conversations.